Trial Profile
Efficacy and Safety of Tolvaptan in Heart Failure Patients with Renal Impairment and Volume Overload Despite the Standard Treatment with Conventional Diuretics
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Jul 2018
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary) ; Diuretics; Furosemide
- Indications Heart failure; Renal impairment
- Focus Therapeutic Use
- Acronyms K-STAR
- 02 Sep 2015 Primary endpoint has been met. (Urinary output), according to an abstract presented at the the ESC Congress 2015: Annual Congress of the European Society of Cardiology
- 02 Sep 2015 Results presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology
- 03 Dec 2012 New trial record